1. From Adjuvant to Metastatic in Melanoma

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Immune Checkpoint Inhibition

5. The Metastatic Setting Dosing

6. CheckMate-067 4-Year Survival Data by PD-L1 Expression

7. CheckMate-067 4-Year Survival Data

8. Brain Metastases CheckMate 204

9. Brain Metastases Australian ABC Trial

10. Brain Metastases Implications for Practice

11. Duration of Therapy

12. Duration of Therapy (cont)

13. Duration of Therapy Implications for Practice

14. The Adjuvant Setting KEYNOTE-054

15. The Adjuvant Setting CheckMate-238

16. Considerations in the Adjuvant Setting

17. Considerations in the Adjuvant Setting (cont)

18. Treating Patients With BRAF-Positive Disease

19. Emerging Approaches

20. Thoughts on When Trials of Investigational Drugs Should Progress to Phase 3

21. Emerging Approaches (cont)

22. irAEs

23. Working Together as a Team

24. Guidelines for Identifying and Managing irAEs

25. Communication

26. Case Example A Patient With Colitis

27. Concluding Remarks

28. Abbreviations

29. Abbreviations (cont)